

**Title:** The Development of Radiopharmaceuticals in Australia

**by**

Michael Druce

Chief Technical Officer, Nuclear Business, Australian Nuclear Science and Technology Organisation (ANSTO)

12:00 pm – 1:00 pm, Monday, 3 August 2015  
Room NA 1.418, GTP building (Ground Floor),  
Deakin University, Waurin Ponds, Geelong, Australia

RSVP – <http://www.deakin.edu.au/research/cisr/workshops/ieee-smc-vic.php>

Professor Saeid Nahavandi or Trish O'Toole  
[trish.otoole@deakin.edu.au](mailto:trish.otoole@deakin.edu.au) or Tel: +61 3 5227 1352

---

### **Abstract**

This talk will give an overview of the use of radioisotopes in medicine, both in Australia and overseas.

ANSTO, as Australia's nuclear agency has contributed significantly to its use in Australia. ANSTO now sells radioisotopes for medical applications not only across Australia and New Zealand but also exports globally with substantial sales in both the USA and Japan.

ANSTO is a government "Research and Development" organisation and all of ANSTO's major nuclear medicine products and processes have been developed internally. However, this development process was undertaken by the operating division, not by the research divisions. This initially occurred after the research divisions failed to develop the products into a market-ready state. Often "Research and Development" are banded together as if they are the same function however our experience has shown that they should be considered as separate functions and managed accordingly. The difference between the research function and the development function will be discussed.

### **Biography:**

Michael Druce is Nuclear Business's Chief Technology Officer and Manager of Client Office activities for the new ANM Plant. He provides technical support for Nuclear Business Projects and Operations.

Michael has extensive experience in the development and manufacture of radioisotopes for both medical and industrial applications. He provides technical advice on ANSTO projects and consulting services to other organisations. He is the technical director for the new ANM Mo-99 Plant and responsible for preparing the plant for operations.

Michael holds a Bachelor of Applied Science (Chemistry) and a Master of Business Administration. He has also graduated from the Australian School of Nuclear Technology and is a Graduate of the Australian Institute of Company Directors. He has over 30 years of experience with both reactor and cyclotron based radioisotopes. He is based at ANSTO's Lucas Heights campus.